Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2022 Results Conference Call February 22, 2023 11:30 AM ET

Company Participants

Wade Walke - SVP, IR

Brett Monia - CEO

Beth Hougen - CFO

Eugene Schneider - Chief Clinical Development Officer

Onaiza Cadoret - Chief Global Product Strategy & Operations Officer

Eric Swayze - EVP, Research

Conference Call Participants

Yanan Zhu - Wells Fargo Securities

Gary Nachman - BMO Capital Markets

Do Kim - Piper Sandler

Gena Wang - Barclays

Yale Jen - Laidlaw & Co.

Paul Matteis - Stifel

Jessica Fye - JP Morgan

Joseph Stringer - Needham & Company

Luca Issi - RBC

Mike Ulz - Morgan Stanley

Myles Minter - William Blair

Yaron Werber - Cowen

Operator

Good morning, and welcome to Ionis Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. [Operator Instructions]. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin, sir.

Wade Walke

Thank you, [Vishnari], Navin. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides to our website that accompany today's call.

With me this morning are Brett Monia, our Chief Executive Officer; Eugene Schneider, Chief Clinical Development Officer; Onaiza Cadoret, Chief Global Product Strategy and Operations Officer; and Beth Hougen, our Chief Financial Officer; and Eric Swayze, our Executive Vice President of Research, will join us for the Q&A portion of the call.

I would like to draw your attention to Slide 3, which contains our forward-looking statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I'll turn the call over to Brett.

Brett Monia

Thanks, Wade. Good morning, everybody, and thanks for joining us today. As we begin this year, we are building on the significant momentum from the key successes we achieved in 2022, highlighted by our progress in advancing our 3 near-term commercial opportunities towards the market.